Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2023
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Novartis. Primary endpoint: Systemic Lupus Erythematosus Responder Index -4 at 60 weeks. Started Mar 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05639114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639114.